JPI-289

Amelparib hydrochloric hydrate (JPI-289, JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM; does not affect cell viability up to 1 mM in rat cortical neuronal cells; attenuates PARP activity restores ATP and NAD+ levels in oxygen glucose deprived (OGD) rat cortical neurons, reduces apoptosis-associated molecules such as apoptosis inducing factor (AIF), cytochrome C and cleaved caspase-3 in the OGD model; JPI-289 is a potential neuroprotective agent which could be useful as a treatment for acute ischaemic stroke. Stroke Phase 2 Clinical

References 1. Kim Y, et al. Clin Exp Pharmacol Physiol. 2017 Jun;44(6):671-679. 2. Kim Y, et al. Mol Neurobiol. 2018 Jan 30. doi: 10.1007/s12035-018-0910-6. View Related Products by Target PARP Stroke